Publicaciones (24) Publicaciones de Manuela González Aparicio

2024

  1. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

    Gene Therapy, Vol. 31, Núm. 9-10, pp. 455-466

2023

  1. Application of a split-Cre system for high-capacity adenoviral vector amplification

    Biotechnology Journal, Vol. 18, Núm. 3

  2. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2021

  1. Adenovirus-mediated inducible expression of a pd-l1 blocking antibody in combination with macrophage depletion improves survival in a mouse model of peritoneal carcinomatosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

  2. AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α Production

    Journal of immunology (Baltimore, Md. : 1950), Vol. 206, Núm. 2, pp. 376-385

  3. Author Correction: Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation (Scientific Reports, (2019), 9, 1, (14172), 10.1038/s41598-019-50627-w)

    Scientific Reports

  4. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  5. Implication of interleukin family in cancer pathogenesis and treatment

    Cancers

  6. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

  7. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

2020

  1. High-capacity adenoviral vectors: Expanding the scope of gene therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

2019

  1. Danio rerio as model organism for adenoviral vector evaluation

    Genes, Vol. 10, Núm. 12

  2. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation

    Scientific Reports, Vol. 9, Núm. 1

  3. Influence of interleukin-8 and neutrophil extracellular trap (NET) formation in the tumor microenvironment: Is there a pathogenic role?

    Journal of Immunology Research, Vol. 2019

2018

  1. Inhibition of adenovirus infection by mifepristone

    Antiviral Research, Vol. 159, pp. 77-83

2017

  1. Adaptation of vectors and drug-inducible systems for controlled expression of transgenes in the tumor microenvironment

    Journal of Controlled Release, Vol. 268, pp. 247-258

  2. X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver

    Gastroenterology, Vol. 152, Núm. 5, pp. 1203-1216.e15

2015

  1. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

  2. Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model

    Gene Therapy, Vol. 22, Núm. 9, pp. 696-706

2013

  1. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice

    Human Molecular Genetics, Vol. 22, Núm. 14, pp. 2929-2940